SEOUL – October 29, 2026 -- Korean biotechnology company CELSET INC. has launched SOLTOX, a botulinum toxin type A brand, in 100 Unit and 200 Unit formulations for international medical aesthetics markets.
SOLTOX combines a 900 kDa complex with a freeze-dried dosage form
The product is built on three technical characteristics: a 900 kDa toxin complex, a lyophilized powder format and an advanced purification process. The powder is reconstituted before administration by qualified medical professionals, in line with product labeling and local requirements.
CELSET states that the 900 kDa figure describes the molecular size of the toxin protein complex, including associated proteins. The company says it does not establish a claim of superior clinical duration or efficacy.
CELSET applies purification and batch controls across preparation, filling and freeze drying
Advanced Botulinum Toxin Purification Technology is used to separate the desired substance from unwanted materials during processing. Quality control procedures cover preparation, filling, freeze drying and batch assessment, all under controlled manufacturing conditions.
Country-level regulation and professional channels will govern SOLTOX availability
SOLTOX broadens CELSET's medical aesthetics portfolio. The company links its international presence to country-level market development, professional relationships and established medical channels.
Availability and use depend on the regulatory requirements of each country. CELSET does not equate its manufacturing characteristics with unverified differences in patient outcomes.